LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The study will assess the effects of 36 weeks of treatment with LCZ696 compared to valsartan
on N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) in patients with chronic heart
failure and preserved left-ventricular ejection fraction.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan